Antibodies are useful tools to characterize the components of the human proteome and to validate potential protein biomarkers discovered through various clinical proteomics efforts. The lack of validation results across various applications for most antibodies often makes it necessary to perform cumbersome investigations to ensure specificity of a particular antibody in a certain application. A need therefore exists for a standardized system for sharing validation data about publicly available antibodies and to allow antibody providers as well as users to contribute and edit experimental evidence data, including data also on the antigen. Here, we describe a new publicly available portal called Antibodypedia (http://www.antibodypedia.org), which has been developed to allow sharing of information regarding validation of antibodies in which providers can submit their own validation results and reliability scores. We report standardized validation criteria and submission rules for applications such as Western blots, protein arrays, immunohistochemistry and immunofluorescence. The contributor is expected to provide experimental evidence and a validation score for each antibody and the users can subsequently provide feedback and comments on the use of the antibody. The database thus provides a virtual resource of publicly available antibodies towards human proteins with accompanying experimental evidence supporting an individual validation score for each antibody in an application-specific manner.
Introduction
One of the great challenges in basic and clinical proteomics, and in bioscience in general, is the lack of well-characterized affinity reagents for many human protein targets. Such protein specific probes could be used to explore the corresponding proteins both in vivo and in vitro, including the necessary validation of potential biomarkers discovered through proteomics-based methods, such as 2-D gels (1) or mass spectrometry (2) . An important factor for the use of protein probes is the quality assurance of the affinity reagents regarding specificity and cross-reactivity (3, 4) . A recent analysis (Berglund, Wester and Uhlen, unpublished) of more than 5,000
antibodies from over 50 commercial providers demonstrated that approximately 50% of the antibodies were found to be non-functional in the immunohistochemistry application tested. This demonstrates the need for standardized ways to validated antibodies, which is further accentuated by the huge dynamic range of proteins in biological systems, as exemplified by the 10 10 -fold difference in concentration between abundant and low abundant serum proteins in human blood (5), making potential cross-reactivity difficult to predict and points to the need to validate affinity reagents in an applications-specific manner.
Antibodies can be used in many different ways to probe protein function and expression ( Table 1 ). Note that for many applications, the protein target are denatured by various agents, such as detergents or formalin, and this means that conformational epitopes obtained by different parts of the protein sequence brought together by the folding process often are no longer present in the assay format. In these cases, it might be preferable to use antibodies recognizing linear epitopes, defined as a recognition region consisting a stretch of consecutive amino acids, normally 8-12 residues (6).
For other applications, such as flow sorting of live cells or therapeutic antibodies, the protein target is usually in a native fold and thus conformational epitopes are usually preferable (7), although linear epitopes might also in some cases be present at the surface of the target protein. The functionality of a particular antibody in a specific application is however hard or even impossible to predict and this emphasize the importance of testing an antibody across different application platforms to investigate the performance during a fixed set of conditions and to establish binding parameters, such as specificity and sensitivity.
An important factor for the generation of affinity reagents is the choice of antigen (8) .
There are at least five different ways to generate the antigen as outlined in Table 2 ranging from the purification of the native protein from natural resources to synthesis of short peptides by chemical means. (11) . The fact that the antigen influences the performance of the generated affinity reagents across different assay platforms demonstrates the importance to publicly disclose the antigen sequence or even better the exact target binding site (epitope) as part of the characteristics for a particular antibody.
It has been suggested that an objective for antibody-based proteomics (4) should be to generate paired antibodies (affinity reagents) recognizing distinct and nonoverlapping epitopes of the target protein to facilitate the quality assessment of the target specificity, but also to allow various formats of "sandwich-based" assays (12) .
This calls for a database shared by the scientific community to allow access of information about antigen information coupled with a specific antibody as an important input in the selection of affinity reagents for a particular assay. Recently, Mathivanan et al (13) described the Human Proteinpedia portal, which is an attempt to share, integrate and present proteomics data in a "wikipedia"-style manner, although the contributor is expected to provide experimental evidence for the data annotated and with the restriction that only the original contributor can edit the data.
Given the complexity of proteomic data, Proteinpedia allows all of the annotated data to be visualized and the aim of the portal is to aid comparison and interpretation, meta-annotations pertaining to samples, method of isolation and experimental platform specific information (13) . The need to be able to share information about antigens and application-specific validation of affinity reagents enforces the need for a conceptually similar database portal for antibodies based on community-based contributions.
Here, we describe an information database which has been developed within the framework of the EU research infrastructure ProteomeBinders (14) , aimed to create a virtual resource of validated antibodies available to the scientific community The portal allows users to share validation results on antibodies and antigens and we report the implementation of four applications and the rules for submission of data. The web portal. The web portal is developed with three slightly different appearances, one for each user group: binder providers, internal reviewers and the public part for end users. The two first user groups need to login in to the portal using their account in order for them to add/modify binders (binder providers) or review binders (reviewers). Having a user account as a binder supplier will grant access to the part of the Antibodypedia portal where new binders can be submitted and previously submitted binder can be modified or enriched with more validation data.
Having a user account, as a reviewer will grant access to the part of the web portal where newly submitted or modified binders need review for compliance to the hereby proposed validation scoring system for each assay. After the supplier has submitted the binders, the binder and validation data will be reviewed to verify concordance with this proposed standard evaluation of the validation experiments. Thereafter, if the submission appears correct the binders will be published on the Antibodypedia.
Validation of antibodies.
The validation using protein arrays were done as described earlier by Nilsson et al. (15) The Western blots were done according to (11) . The immunohistochemistry validation has been described by Kampf et al (16) . The confocal analysis (immunofluorescence) was performed as described by Barbe et al (17) .
Results
The rules for submission of data. A new database for sharing antibody and antigen information has been developed. The portal is gene-centric based on human genes as defined by Ensembl (18, 19) . The principle of the information flow is shown in figure   1 . For each application, a standard set of categories has been established (Supplementary Table S1 ) and these are grouped into three main validation scores; (i) supportive, (ii) uncertain or (iii) non-supportive. In order to submit data about an antibody, the provider needs to submit a validation based on experimental evidence that must be disclosed. Only antibodies scored as supportive or uncertain needs to be (21), planar microarrays (15) and suspension arrays (22) . Here, we propose four validation scores for validation criteria using a planar array (Supplementary Table S1 ). Validation score 1 (supportive) shows high specific binding of the antibody to the target antigen reacting with no signal above 15% of the specific signal to all other antigens on the protein array. Validation score 4 (nonsupportive) on the other hand, shows that at least one antigen has more than 40% of the signal obtained for the target protein or three antigens showing more than 15%
signal as compared to the signal of the binding to the target antigen. In figure 2 , examples of results from the supportive category (score 1), uncertain (score 2) and non-supportive (score 4) are shown.
Western blot analysis. A frequently used assay for validation of antibodies is
Western blot in which a tissue or cell extract is denaturated with detergent (SDS) and all proteins are separated according to size using electrophoresis followed by blotting to a membrane and analyzed using a specific antibody (23) . In this manner, specificity of an antibody can be analyzed together with a comparison between the experimental size and the predicted size of the target protein as determined from the genome sequence. This analysis also allows probing for size differences of the protein target caused by splicing, proteolysis or modification, such as glycosylation. Seven categories for the validation is proposed (Supplementary Table S1 ) in which three are "supportive", two "uncertain" and two "non-supportive". Examples from validation score 1 (supportive), 5 (uncertain) and 7 (non-supportive) are shown in Figure 2 .
Note, that since only a limited amounts of tissues or cells can be analyzed on a
Western blot, a blank gel (validation score 4) only means that the protein is not present in the tissue or cell extracts analyzed and that another selection of tissue or cell extracts might yield a band of correct size.
Immunohistochemistry analysis. The analysis using immunohistochemistry (IHC)
allows in situ profiling of protein targets from various organs and tissues usually prepared by formalin fixation and imbedded in paraffin (16) . The use of tissue micro array (24) allows many hundreds of samples to be collected on a single slide and analyzed in parallel. The evaluation of IHC is relatively subjective with the result of the staining compared with expected expression profiles as determined by literature or bioinformatics, such as the presence of transmembrane regions or Interpro domains (25) . Here, we propose that the validation is grouped into five validation scores (Supplementary Table S1 ), in which score 1 (supportive) can only be obtained if two paired antibodies with separate and non-overlapping epitopes show the same or near identical staining. Validation score 2 is also supportive and this category is used when the staining pattern is consistent with experimental and/or bioinformatics data. Figure   2 show examples of IHC images scored within the score 2 (supportive), 3 (uncertain) or 5 (non-supportive).
Immunofluorescent analysis. Confocal microscopy is a powerful method for analysis of subcellular localization of protein targets using fluorescently labeled antibodies (17) . A complication for validating confocal data is that many proteins are distributed in several compartments and that the analysis, similar to IHC, is subjective and depends on data from literature and/or bioinformatics. The subcellular localization prediction methods are still not yet precise (26) and therefore cannot be used extensively to support or discard an antibody pattern using confocal microscopy.
Seven categories are proposed for the validation of antibodies by immunofluorescence (Supplementary Table S1 
Validation of monospecific antibodies generated with the Human Protein Atlas
program. The antibodies generated during a period of 17 months within the framework of the Human Protein Atlas effort (27) were subjected to the validation as outlined in figure 2 and Supplementary Table S1 . Altogether 3900 antibodies were analyzed on at least one of the four application platforms and all the results were submitted to the Antibodypedia portal. Figure 4 
Discussion
Here, we show for the first time a portal to share validation data for publicly available antibodies with accompanying data about the antigen. This new portal thus provides a web-based submission format to allow any antibody provider to submit data about their antibodies with validation scores for various applications. It is only possible to submit antibodies available to the scientific community and the portal provides direct links to allow users to obtain the corresponding antibody after reviewing the validation information submitted to the database. The database relies on validation scores, submitted by the antibody provider, based on a standard set of validation criteria, but it is important to point out that the validation is subjective in nature. It is thus mandatory to submit the primary data, usually in the form of an image with text annotation, to allow all users to review the data behind the validation score. Users are also allowed to send in comments to the portal about the use of a particular antibody and in this manner both positive and negative results from a particular antibody can be shared among the scientific community. The curation of the data in the portal is important, but we suggest that this curation should only involve checking that the standardized formats and the submission rules have been followed and that the validation score is supported by evidence data.
The validation score is application-specific with the underlying understanding that antibodies can behave very differently in different applications. The results can also vary depending on the sample preparation used and even the origin of the sample. A description of the sample and the sample preparation must therefore be submitted as part of the validation score. More application, as exemplified in Table 2 , can be added to the portal, but for each application a standard set of validation categories must be defined and we suggest that these should subsequently be stratified into the main three validation categories (i) supportive, (ii) uncertain and (iii) non-supportive. The standards for sharing antibody data should adhere to an international initiatives, in a similar manner as has already been done for protein interaction data (28).
It is important to point out that the validation of antibodies regarding specificity is subjective and depends on the concentration and dynamic range of the target protein, There are many different types of affinity reagent that can be used as protein probes to explore the human proteome (29) . For research applications, antibodies are by far the most used affinity reagents, including monoclonal antibodies generated by hybridoma technology (30) or monospecific antibodies, in which the polyclonal antibody mixture is affinity purified using synthetic peptides (31) or protein fragments (15) . However, the rapid development of new selection methods (29) might make it possible in the future to create renewable affinity reagents in a high-throughput manner using in vitro selection principles. Future versions of the Antibodypedia portal should therefore allow the inclusion also of recombinant affinity reagents, including new protein scaffolds (32), such as affibodies and anchyrins, and nucleic-acid based affinity reagents, such as aptamers. It might also be relevant to also include information about small molecular binders to protein targets, such as peptides or low molecular weight organic synthesis products.
The first version of this portal contains information about 3900 antibodies generated within the framework of the Human Protein Atlas program (11), but in the future all antibody providers are invited to submit their own antibodies to the virtual resource.
The Antibodypedia portal will thus contain all antibodies in which web-submission have been made by the antibody provider. This is in contrast to the Human Protein Atlas portal (www.proteinatlas.org), which only contains antibodies approved by a comprehensive analysis of immunohistochemistry using a standardized set of 48 tissues, 216 cancer patients, 47 human cell lines and 12 primary cells (27) . The protein atlas thus provides expression profiles of human proteins in tissues and cells based on selected antibodies, while the Antibodypedia portal contains any antibody validated by at least one of the applications included in the portal and independent of its presence or absence in the immunohistochemistry-based protein atlas portal.
In summary, we present a new community-based virtual resource for antibodies that have been validated in an application-specific manner. Proposed validation criteria are presented for four common research applications, but more applications can be added in due course. The objective of the portal is to allow antibody providers to submit validation results for their antibodies and to aid users of antibodies to select antibodies functional in a particular assay. The ultimate aim is to create a resource of validated antibodies to all human proteins to facilitate the experimental "annotation" of the human proteome and to facilitate the analysis of potential biomarkers discovered through various clinical proteomics efforts. 
